keyword
MENU ▼
Read by QxMD icon Read
search

PDAC

keyword
https://www.readbyqxmd.com/read/29053398/the-involvement-of-lncrnas-in-the-development-and-progression-of-pancreatic-cancer
#1
Li Duguang, He Jin, Qian Xiaowei, Xu Peng, Wang Xiaodong, Li Zhennan, Qian Jianjun, Yao Jie
Pancreatic cancer is one of the most malignant tumors that are difficult to diagnose at its early stage and there is no effective therapy. Recent studies uncovered that many non-protein-coding RNAs including the class of long noncoding RNAs (lncRNAs) are differentially expressed in various types of tumors and they are potent regulators of tumor progression and metastasis. LncRNA can mediate tumor initiation, proliferation, migration and metastasis through modulating epigenetic modification, alternative splicing, transcription, and protein translation...
October 20, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29052140/prion-protein-family-contributes-to-tumorigenesis-via-multiple-pathways
#2
Xiaowen Yang, Zhijun Cheng, Lihua Zhang, Guiru Wu, Run Shi, Zhenxing Gao, Chaoyang Li
A wealth of evidence suggests that proteins from prion protein (PrP) family contribute to tumorigenesis in many types of cancers, including pancreatic ductal adenocarcinoma (PDAC), breast cancer, glioblastoma, colorectal cancer, gastric cancer, melanoma, etc. It is well documented that PrP is a biomarker for PDAC, breast cancer, and gastric cancer. However, the underlying mechanisms remain unclear. The major reasons for cancer cell-caused patient death are metastasis and multiple drug resistance, both of which connect to physiological functions of PrP expressing in cancer cells...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29050937/integrated-expression-profiling-of-potassium-channels-identifys-kcnn4-as-a-prognostic-biomarker-of-pancreatic-cancer
#3
Shuheng Jiang, Lili Zhu, Jianyu Yang, Lipeng Hu, Jianren Gu, Xin Xing, Yongwei Sun, Zhigang Zhang
Dysregulated potassium (K(+)) channels have previously been shown to promote the development and progression of many types of cancers. Meanwhile, K(+) channels are particularly important in regulating the endocrine and exocrine functions of pancreas. However, the expression pattern and prognostic significance of K(+) channels in pancreatic ductal adenocarcinoma (PDAC) remain unknown. In this study, by screening a GEO dataset containing 36 microdissected PDAC and matching normal pancreatic tissue samples, four differentially expressed K(+) channels (KCNJ5, KCNJ16, KCNN4 and KCNK1) were identified in PDAC...
October 16, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29050294/the-density-of-mast-cells-c-kit-and-tryptase-correlates-with-each-other-and-with-angiogenesis-in-pancreatic-cancer-patients
#4
Michele Ammendola, Cosmo Damiano Gadaleta, Adam Enver Frampton, Tullio Piardi, Riccardo Memeo, Valeria Zuccalà, Maria Luposella, Rosa Patruno, Nicola Zizzo, Pietro Gadaleta, Patrick Pessaux, Rosario Sacco, Giuseppe Sammarco, Girolamo Ranieri
Literature data suggest that inflammatory cells such as mast cells (MCs) are involved in angiogenesis. MCs can stimulate angiogenesis by releasing of well identified pro-angiogenic cytokines stored in their cytoplasm. In particular, MCs can release tryptase, a potent in vivo and in vitro pro-angiogenic factor. Nevertheless, few data are available concerning the role of MCs positive to tryptase in primary pancreatic cancer angiogenesis. This study analyzed the correlation between mast cells positive to c-Kit receptor (c-Kit(+) MCs), the density of MCs expressing tryptase (MCD-T) and microvascular density (MVD) in primary tumor tissue from patients affected by pancreatic ductal adenocarcinoma (PDAC)...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29050264/the-microrna-expression-signature-of-pancreatic-ductal-adenocarcinoma-by-rna-sequencing-anti-tumour-functions-of-the-microrna-216-cluster
#5
Keiichi Yonemori, Naohiko Seki, Tetsuya Idichi, Hiroshi Kurahara, Yusaku Osako, Keiichi Koshizuka, Takayuki Arai, Atsushi Okato, Yoshiaki Kita, Takaaki Arigami, Yuko Mataki, Yuko Kijima, Kosei Maemura, Shoji Natsugoe
We analysed the RNA sequence-based microRNA (miRNA) signature of pancreatic ductal adenocarcinoma (PDAC). Aberrantly expressed miRNAs were successfully identified in this signature. Using the PDAC signature, we focused on 4 clustered miRNAs, miR-216a-5p, miR-216a-3p, miR-216b-5p and miR-216b-3p on human chromosome 2p16.1. All members of the miR-216 cluster were significantly reduced in PDAC specimens. Ectopic expression of these miRNAs suppressed cancer cell aggressiveness, suggesting miR-216 cluster as anti-tumour miRNAs in PDAC cells...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29048549/curcumin-sensitizes-pancreatic-cancer-cells-to-gemcitabine-by-attenuating-prc2-subunit-ezh2-and-the-lncrna-pvt1-expression
#6
Kazuhiro Yoshida, Shusuke Toden, Preethi Ravindranathan, Haiyong Han, Ajay Goel
Development of resistance to chemotherapeutic drugs is a major challenge in the care of patients with pancreatic ductal adenocarcinoma (PDAC). Acquired resistance to chemotherapeutic agents in PDAC has been linked to a subset of cancer cells termed 'cancer stem cells' (CSCs). Therefore, an improved understanding of the molecular events underlying the development of pancreatic CSCs is required to identify new therapeutic targets to overcome chemoresistance. Accumulating evidence indicates that curcumin, a phenolic compound extracted from turmeric, can overcome de novo chemoresistance and re-sensitize tumors to various chemotherapeutic agents...
October 1, 2017: Carcinogenesis
https://www.readbyqxmd.com/read/29045505/surfaceome-profiling-enables-isolation-of-cancer-specific-exosomal-cargo-in-liquid-biopsies-from-pancreatic-cancer-patients
#7
J Castillo, V Bernard, F A San Lucas, K Allenson, M Capello, D U Kim, P Gascoyne, F C Mulu, B M Stephens, J Huang, H Wang, A A Momin, R O Jacamo, M Katz, R Wolff, M Javle, G Varadhachary, I I Wistuba, S Hanash, A Maitra, H Alvarez
Background: Detection of circulating tumor DNA (ctDNA) can be limited due to their relative scarcity in circulation, particularly while patients are actively undergoing therapy. Exosomes provide a vehicle through which cancer-specific material can be enriched from the compendium of circulating non-neoplastic tissue-derived nucleic acids. We performed a comprehensive profiling of the pancreatic ductal adenocarcinoma (PDAC) exosomal "surfaceome" in order to identify surface proteins that will render liquid biopsies amenable to cancer-derived exosome enrichment for downstream molecular profiling...
September 25, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29044544/primary-systemic-therapy-in-resectable-pancreatic-ductal-adenocarcinoma-using-mfolfirinox-a-pilot-study
#8
Robert de W Marsh, Mark S Talamonti, Marshall S Baker, Mitchell Posner, Kevin Roggin, Jeffrey Matthews, Daniel Catenacci, Mark Kozloff, Blase Polite, Michele Britto, Chi Wang, Hedy Kindler
BACKGROUND AND OBJECTIVES: Surgery followed by gemcitabine and/or a fluoropyrimidine is standard therapy for resectable PDAC. mFOLFIRINOX (oxaliplatin 85 mg/m(2) , irinotecan 180 mg/m(2) , leucovorin 400 mg/m(2) Day 1, 5-FU 2400 mg/m(2)  × 48 h IV, peg-filgrastim 6 mg SQ day 3, every 14 days) has substantial activity in metastatic PDAC. We wished to determine the tolerability/efficacy of peri-operative mFOLFIRINOX in resectable PDAC. METHODS: Patients with resectable PDAC (ECOG PS 0/1) received four cycles of mFOLFIRINOX pre- and post-surgery...
October 16, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29043580/a-comprehensive-assessment-of-accurate-lymph-node-staging-and-preoperative-detection-in-resected-pancreatic-cancer
#9
Toshiro Masuda, Amanda M Dann, Irmina A Elliott, Hideo Baba, Stephen Kim, Alireza Sedarat, V Raman Muthusamy, Mark D Girgis, O Joe Hines, Howard A Reber, Timothy R Donahue
BACKGROUND: The current (seventh edition) American Joint Commission on Cancer (AJCC) Staging System for pancreatic ductal adenocarcinoma (PDAC) dichotomizes pathologic lymph node (LN) involvement into absence (pN0) or presence (pN1) of disease. The recently announced eighth edition also includes stratification on the number of positive nodes. Furthermore, LNs detected on preoperative imaging (CT, MRI, or endoscopic ultrasound-EUS) are considered to be pathologically involved in other gastrointestinal cancers...
October 17, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/29043413/cholecystokinin-receptor-antagonist-alters-pancreatic-cancer-microenvironment-and-increases-efficacy-of-immune-checkpoint-antibody-therapy-in-mice
#10
Jill P Smith, Shangzi Wang, Sandeep Nadella, Sandra A Jablonski, Louis M Weiner
Advanced pancreatic ductal adenocarcinoma (PDAC) has typically been resistant to chemotherapy and immunotherapy; therefore, novel strategies are needed to enhance therapeutic response. Cholecystokinin (CCK) has been shown to stimulate growth of pancreatic cancer. CCK receptors (CCKRs) are present on pancreatic cancer cells, fibroblasts, and lymphocytes. We hypothesized that CCKR blockade would improve response to immune checkpoint antibodies by promoting influx of tumor-infiltrating lymphocytes (TILs) and reducing fibrosis...
October 17, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29040676/dysbindin-promotes-progression-of-pancreatic-ductal-adenocarcinoma-via-direct-activation-of-pi3k
#11
Cheng Fang, Xin Guo, Xing Lv, Ruozhe Yin, Xiaohui Lv, Fengsong Wang, Jun Zhao, Xuebiao Yao, Yong Chen
Pancreatic ductal adenocarcinoma (PDAC) represents a biggest challenge in clinic oncology due to its invasiveness and lack of targeted therapeutics. Our recent study showed that schizophrenia susceptibility factor dysbindin exhibited significant higher level in serum of PDAC patients. However, the functional relevance of dysbindin in PDAC is still unclear. Here, we show that dysbindin promotes tumor growth both in vitro and in vivo by accelerating the G1/S phase transition in cell cycle via PI3K/AKT signaling pathway...
October 6, 2017: Journal of Molecular Cell Biology
https://www.readbyqxmd.com/read/29039574/tgf-%C3%AE-1-induced-cell-migration-in-pancreatic-carcinoma-cells-is-rac1-and-nox4-dependent-and-requires-rac1-and-nox4-dependent-activation-of-p38%C3%A2-mapk
#12
David Witte, Tobias Bartscht, Roland Kaufmann, Ralph Pries, Utz Settmacher, Hendrik Lehnert, Hendrik Ungefroren
Transforming growth factor (TGF)-β promotes epithelial-mesenchymal transition and cell invasion of cancer cells in part through the small GTPase RAC1. Since RAC1 can signal through reactive oxygen species (ROS), we probed the role of the ROS-producing NADPH oxidase (NOX) and p38 mitogen-activated protein kinase (MAPK) in mediating TGF-β1/RAC1-driven random cell migration (chemokinesis). Although the NOX isoforms NOX2, 4, 5, 6, and RAC1 were readily detectable by RT-PCR in pancreatic ductal adenocarcinoma (PDAC)-derived Panc1 and Colo357 cells, only NOX4 and RAC1 were expressed at higher levels comparable to those in peripheral blood monocytes...
October 12, 2017: Oncology Reports
https://www.readbyqxmd.com/read/29038348/stk33-promotes-growth-and-progression-of-pancreatic-cancer-as-a-critical-downstream-mediator-of-hif-1%C3%AE
#13
Fanyang Kong, Xiangyu Kong, Yiqi Du, Ying Chen, Xuan Deng, Jianwei Zhu, Jiawei Du, Lei Li, Zhiliang Jia, Dacheng Xie, Zhaoshen Li, Keping Xie
The serine/threonine kinase STK33 has been implicated in cancer cell proliferation. Here we provide evidence of a critical role for STK33 in the pathogenesis and metastatic progression of pancreatic ductal adenocarcinoma (PDAC). STK33 expression in PDAC was regulated by the hypoxia-inducible transcription factor HIF-1α. In human PDAC specimens, STK33 was overexpressed and associated with poor prognosis. Enforced STK33 expression promoted PDAC proliferation, migration, invasion and tumor growth, whereas STK33 depletion exerted opposing effects...
October 16, 2017: Cancer Research
https://www.readbyqxmd.com/read/29033025/the-clinical-utility-of-immunoglobulin-g4-in-the-evaluation-of-autoimmune-pancreatitis-and-pancreatic-adenocarcinoma
#14
Linda M Pak, Mark A Schattner, Vinod Balachandran, Michael I D'Angelica, Ronald P DeMatteo, T Peter Kingham, William R Jarnagin, Peter J Allen
BACKGROUND: Elevation in the serum immunoglobulin-G4 (IgG4) level has been used as a diagnostic marker to distinguish autoimmune pancreatitis (AIP) from pancreatic ductal adenocarcinoma (PDAC), but its true utility is ill-defined. This study evaluates the clinical utility of IgG4 in differentiating AIP from PDAC. METHODS: All patients evaluated in the hepatopancreaticobiliary surgery clinics with measured serum IgG4 were included. Patients were divided into normal IgG4 (<135 mg/dL) and elevated IgG4 (≥135 mg/dL) groups...
October 9, 2017: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/29029505/the-deubiquitinating-enzyme-usp5-promotes-pancreatic-cancer-via-modulating-cell-cycle-regulators
#15
Brajesh P Kaistha, Anja Krattenmacher, Johannes Fredebohm, Harald Schmidt, Diana Behrens, Miriam Widder, Thilo Hackert, Oliver Strobel, Jörg D Hoheisel, Thomas M Gress, Malte Buchholz
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. With an overall five-year survival rate remaining below 6%, there is an explicit need to search for new molecular targets for therapeutic interventions. We undertook a barcode labelled short-hairpin (shRNA) library screen in pancreatic cancer cells in order to identify novel genes promoting cancer survival and progression. Among the candidate genes identified in this screen was the deubiquitinase USP5, which subsequent gene expression analyses demonstrated to be significantly upregulated in primary human pancreatic cancer tissues...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29029495/metadherin-promotes-metastasis-by-supporting-putative-cancer-stem-cell-properties-and-epithelial-plasticity-in-pancreatic-cancer
#16
Kensuke Suzuki, Shigetsugu Takano, Hideyuki Yoshitomi, Hitoe Nishino, Shingo Kagawa, Hiroaki Shimizu, Katsunori Furukawa, Masaru Miyazaki, Masayuki Ohtsuka
Pancreatic ductal adenocarcinoma (PDAC) has a high metastatic potential. However, the mechanism of metastatic colonization in PDAC remains poorly understood. Metadherin (MTDH) has emerged in recent years as a crucial mediator of metastasis in several cancer types, although the biological role of MTDH in PDAC has not been investigated. Here, we demonstrated the functional roles of MTDH in PDAC progression, especially focusing on the metastatic cascade. In vitro studies showed that MTDH provides cancer stem cell (CSC) properties in metastatic PDAC cells and contributes to anoikis resistance with epithelial characteristics in PDAC cells...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29026148/exclusive-and-combined-use-of-statins-and-aspirin-and-the-risk-of-pancreatic-cancer-a-case-control-study
#17
Livia Archibugi, Matteo Piciucchi, Serena Stigliano, Roberto Valente, Giulia Zerboni, Viola Barucca, Michele Milella, Patrick Maisonneuve, Gianfranco Delle Fave, Gabriele Capurso
Data on the association between aspirin and statin use and Pancreatic Ductal AdenoCarcinoma (PDAC) risk are conflicting. These drugs are often co-prescribed, but no studies evaluated the potential combined or confounding effect of the two at the same time. We aimed to investigate the association between aspirin and statin exclusive and combined use and PDAC occurrence. Data on environmental factors, family and medical history were screened in a case-control study. PDAC cases were matched to controls for age and gender...
October 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29024890/a-systematic-review-of-economic-evaluation-in-pancreatic-ductal-adenocarcinoma
#18
REVIEW
Claire Gérard, Philippe Fagnoni, Angélique Vienot, Christophe Borg, Samuel Limat, Franck Daval, François Calais, Julie Vardanega, Marine Jary, Virginie Nerich
OBJECTIVES: The economic evaluation (EE) of healthcare interventions has become a necessity. However, high quality needs to be ensured in order to achieve validated results and help making informed decisions. Thus, the objective of the present study was to systematically identify and review published pancreatic ductal adenocarcinoma-related EEs and to assess their quality. METHODS: Systematic literature research was conducted in PubMed and Cochrane to identify published EEs between 2000 and 2015...
October 9, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29017830/suvmax-after-18-fluoro-deoxyglucose-positron-emission-tomography-computed-tomography-a-tool-to-define-treatment-strategies-in-pancreatic-cancer
#19
Ilaria Pergolini, Stefano Crippa, Matteo Salgarello, Giulio Belfiori, Stefano Partelli, Giacomo Ruffo, Alessandro Pucci, Giuseppe Zamboni, Massimo Falconi
BACKGROUND: (18)fluoro-deoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) might be a useful tool in the management of pancreatic ductal adenocarcinoma (PDAC). AIMS: The aim of this study was to analyze maximum standard uptake value (SUVmax) after 18FDG-PET/CT as predictor of survival outcomes and method to determine treatment strategies. METHODS: A consecutive series of patients who underwent preoperative 18FDG-PET/CT and subsequent resection for PDAC were retrospectively reviewed...
September 22, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28993833/do-anti-stroma-therapies-improve-extrinsic-resistance-to-increase-the-efficacy-of-gemcitabine-in-pancreatic-cancer
#20
REVIEW
Chen Liang, Si Shi, Qingcai Meng, Dingkong Liang, Shunrong Ji, Bo Zhang, Yi Qin, Jin Xu, Quanxing Ni, Xianjun Yu
Pancreatic ductal adenocarcinoma (PDAC) is among the most devastating human malignancies, with approximately 20-30% of PDAC patients receiving the surgical resection with curative intent. Although many studies have focused on finding ideal "drug chaperones" that facilitate and/or potentiate the effects of gemcitabine (GEM) in pancreatic cancer, a significant benefit in overall survival could not be demonstrated for any of these combination therapies in PDAC. Given that pancreatic cancer is characterized by desmoplasia and the dual biological roles of stroma in pancreatic cancer, we reassess the importance of stroma in GEM-based therapeutic approaches in light of current findings...
October 9, 2017: Cellular and Molecular Life Sciences: CMLS
keyword
keyword
29217
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"